Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia

Dasatinib, an effective second-generation tyrosine kinase inhibitor, is used to treat breakpoint cluster region-Ableson-positive chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphocytic leukemia. One common adverse event associated with dasatinib use is fluid retention, includi...

Descripción completa

Detalles Bibliográficos
Autores principales: Makimoto, Go, Misawa, Mahito, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108759/
https://www.ncbi.nlm.nih.gov/pubmed/35585905
http://dx.doi.org/10.1016/j.rmcr.2022.101662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108759/
https://www.ncbi.nlm.nih.gov/pubmed/35585905
http://dx.doi.org/10.1016/j.rmcr.2022.101662

Ejemplares similares